Surmodics Inc. (SRDX) has agreed to be acquired by GTCR, a private equity firm, for $43.00 per share in cash, equating to a total equity value of roughly $627 million.
The company has developed Drug-coated balloons or DCB devices for use in vascular interventions for the treatment of peripheral artery disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com